News | June 08, 2015

Mevion Medical Systems First to Open Back-to-Back Proton Therapy Centers

New Jersey’s Robert Wood Johnson University Hospital treats first patients with the Mevion S250 system weeks after Ackerman Cancer Center in Florida

Mevion, S250, Robert Wood Johnson University Hospital, back-to-back, proton

June 8, 2015 - The Mevion S250 proton therapy system at Robert Wood Johnson University Hospital (RWJUH) is now treating patients, less than four weeks after the first Mevion patient was treated at Ackerman Cancer Center. The occasion marks the first time a proton manufacturer has simultaneously brought up two distinct facilities.

The first two patients treated at RWJUH included a young man with a spinal myxopapillary ependymoma, a cancer that affects the spinal canal. His treatment began on June 5. A second patient with a recurrent brain tumor began treatment on May 27; this patient had received full doses of radiation in the past, and re-treating him with other technologies would have proved difficult. RWJUH, in New Brunswick, New Jersey, is the flagship Cancer Hospital of Rutgers Cancer Institute of New Jersey and the principal teaching hospital of Rutgers Robert Wood Johnson Medical School.

Proton therapy provides targeted treatment to cancer cells and causes less damage to surrounding healthy tissues than photon radiation. This makes it an ideal option for pediatric and adult patients with tumors in sensitive locations, such as near the heart, brain and spine.

Traditionally, proton therapy systems have required the development of new football-field-sized facilities that have ended up costing hundreds of millions of dollars to build and operate. Because only a limited number of cancer centers have this kind of capital or space, there has been a lack of patient access to this important treatment modality. The Mevion S250 is the world's smallest single-room proton therapy system and can be readily integrated into any size cancer facility – existing or new. The result is a proton therapy solution that is 75 percent smaller and uses as much as 90 percent less energy, resulting in significantly lower capital and operating costs.

"The MEVION S250 provides RWJUH with a compact, high-quality delivery system to include in our suite of patient treatment options," said Bruce Haffty, M.D., chief of radiation oncology at RWJUH and professor and chairman of the Department of Radiation Oncology at the Cancer Institute of New Jersey, Robert Wood Johnson Medical School and New Jersey Medical School at Rutgers University. "This is an important milestone in cancer therapy for patients in this region. We can now treat patients in less time with fewer side effects with a very targeted form of radiation therapy."

RWJUH is fully accredited by the American College of Surgeons Commission on Cancer.

"We always strive for excellence in cancer treatment," said Atif Khan, M.D., a radiation oncologist at Rutgers Cancer Institute of New Jersey and associate professor of radiation oncology at Rutgers Robert Wood Johnson Medical School. "I am excited to see the benefits that the Mevion S250 brings to the patients at our proton center."

The S250 began treating patients at Ackerman Cancer Center - a physician-owned facility in Jacksonville, Florida - on April 30 and is currently treating 24 patients per day. Mevion S250 systems are currently being installed at four additional sites in the United States, including University Hospitals Health System in Cleveland, where the superconducting synchrocyclotron accelerator is scheduled to be delivered at the end of June. Other installation sites are: Stephenson Cancer Center at the University of Oklahoma in Oklahoma City; University of Florida Health Cancer Center at Orlando Health; and MedStar Georgetown University Hospital's Lombardi Comprehensive Cancer Center in Washington, D.C.

For more information: www.mevion.com

Related Content

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape
Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Feature | Proton Therapy | May 27, 2020 | By Minesh Mehta, M.D.
Radiation therapy has advanced significantly in the last few decades as a result of a continued technological revolut
Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve.

Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve. Getty Images

Feature | Oncology Information Management Systems (OIMS) | May 27, 2020 | By Reshu Gupta
In the history of medicine, researchers have found cures for many diseases, but cancer has been elusive.
The global radiation therapy market is expected to reach $10.11 billion in 2024, witnessing growth at a CAGR of 3.38%, over the period 2020-2024.
News | Proton Therapy | May 20, 2020
May 20, 2020 — ResearchAndMarkets.com has released its latest report, the ...
An innovative radiation treatment that could one day be a valuable addition to conventional radiation therapy for inoperable brain and spinal tumors is a step closer, thanks to new research led by University of Saskatchewan (USask) researchers at the Canadian Light Source (CLS).

USask PhD bio-medical engineering student Farley Chicilo at the Canadian Light Source synchrotron at University of Saskatchewan. Photo courtesy of Canadian Light Source, University of Saskatchewan

News | Radiation Therapy | May 14, 2020
May 14, 2020 — An innovative radiation treatment t
Medical University of South Carolina researchers have developed and validated prediction tools, known as nomograms, that could be used to help prevent delays in the initiation of radiotherapy after surgery for head and neck cancer

 

Evan Graboyes, M.D., and his team believe their nomogram tools will improve survival rates for head and neck cancer patients. Photo courtesy of MUSC Hollings Cancer Center

 

News | Radiation Oncology | May 14, 2020
May 14, 2020 — More than 65,000 Americans are diagnosed annually with head and neck cancer, which most often occurs i
Due to ongoing health concerns related to the spread of the Coronavirus (COVID-19) as well as global travel restrictions, the American Association of Physicists in Medicine (AAPM) has decided to evolve the Joint AAPM/COMP (Canadian Organization of Medical Physicists) Meeting content into a virtual (completely online) meeting in place of the in-person meeting originally scheduled for July 12-16, 2020, in Vancouver, BC.
News | AAPM | May 11, 2020
May 11, 2020 — Due to ongoing health concerns related to the spread of the Coronavirus (...
Figure 1: CT image of lesions in different planes

Figure 1: CT image of lesions in different planes.

Sponsored Content | Case Study | Radiation Oncology | April 30, 2020 | By Christopher Bowen, M.S., DABR